Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 9, 2017
Chronic lymphocytic leukemia: pathophysiology and current therapyJun Takizawa
International Journal of Hematology|April 8, 2020
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?Junji Suzumiya, Jun Takizawa
The American Journal of Surgical Pathology|September 16, 2016
Clinicopathological, Cytogenetic, and Prognostic Analysis of 131 Myeloid Sarcoma PatientsKeisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 19, 2008
[Prevention of phlebitis caused by vinorelbine chemotherapy in outpatients with breast cancer]Yukiko Yokota, Tomoko Suzuki, Takeshi Narahashi, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|June 7, 2021
Real World Treatment Practices for Chronic Lymphocytic Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR)Jun Takizawa, Koji Izutsu, Hirokazu Nagai, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|June 7, 2021
Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)Koji Izutsu, Junji Suzumiya, Jun Takizawa, et al.
BMJ Open Ophthalmology|September 17, 2019
The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective studyJun Ominato, Tokuhide Oyama, Hiroyuki Cho, et al.
Cancer Science|March 31, 2016
MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphomaKeisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, et al.
Leukemia & Lymphoma|February 1, 2013
MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphomaMinoru Kojima, Hidekazu Nishikii, Jun Takizawa, et al.
Japanese Journal of Clinical Oncology|November 27, 2020
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemiaKoji Izutsu, Tomohiro Kinoshita, Jun Takizawa, et al.
Pageof 8